LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Aandelen Lijst・MediciNova Inc

MediciNova Inc

Gesloten

SectorGezondheidszorg

1.31

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.28

Max

1.32

Belangrijke statistieken
By Trading Economics
Inkomsten	216K -2.6M
Verkoop	35K 187K
EPS	-0.05
Winstmarge	-1,383.144
Werknemers	6
EBITDA	63K -2.8M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+506.06% upside

Dividenden
By Dow Jones
Volgende Winsten	12 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-2M 67M
Vorige openingsprijs	1.31
Vorige sluitingsprijs	1.31

Nieuwssentiment

By Acuity

26%

74%

59 / 344 Rangschikking in Healthcare

MediciNova Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 jun 2026, 21:51 UTC

Belangrijke Marktbewegers

Merlin Shares Rally After Defense Department's Design Review Wraps

4 jun 2026, 23:46 UTC

Marktinformatie

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 jun 2026, 23:44 UTC

Marktinformatie

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 jun 2026, 23:42 UTC

Acquisities, Fusies, Overnames

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 jun 2026, 23:41 UTC

Acquisities, Fusies, Overnames

Energy Resources of Australia to Enter Trading Halt

4 jun 2026, 23:34 UTC

Marktinformatie

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 jun 2026, 23:31 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

4 jun 2026, 23:31 UTC

Marktinformatie

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 jun 2026, 23:31 UTC

Marktinformatie

Global Equities Roundup: Market Talk

4 jun 2026, 23:08 UTC

Marktinformatie

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 jun 2026, 22:41 UTC

Marktinformatie

Australia Shares Set to Rise at the Open -- Market Talk

4 jun 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

4 jun 2026, 20:44 UTC

Acquisities, Fusies, Overnames

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 jun 2026, 20:16 UTC

Marktinformatie

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 jun 2026, 20:15 UTC

Acquisities, Fusies, Overnames

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 jun 2026, 19:46 UTC

Marktinformatie

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 jun 2026, 19:38 UTC

Marktinformatie

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 jun 2026, 19:30 UTC

Marktinformatie

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 jun 2026, 18:47 UTC

Acquisities, Fusies, Overnames

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 jun 2026, 18:38 UTC

Winsten

Money Quote: Tech Weakness in Context -- WSJ

4 jun 2026, 18:24 UTC

Winsten

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 jun 2026, 17:09 UTC

Marktinformatie

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 jun 2026, 16:58 UTC

Winsten

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 jun 2026, 16:46 UTC

Marktinformatie

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 jun 2026, 16:38 UTC

Winsten

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 jun 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

4 jun 2026, 16:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

4 jun 2026, 16:13 UTC

Marktinformatie

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 jun 2026, 16:11 UTC

Marktinformatie

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 jun 2026, 15:56 UTC

Marktinformatie

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Peer Vergelijking

Prijswijziging

MediciNova Inc Prognose

Koersdoel

By TipRanks

506.06% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 8 USD 506.06%

Hoogste 10 USD

Laagste 6 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor MediciNova Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan MediciNova Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

59 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.